图3 HER2-low和HER2-negative TNBC中肿瘤细胞的不同的动态进化特征 这些结果表明,HER2-low和HER2-negative TNBC具有不同的肿瘤进化特征。 HER2-negative TNBC高表达良好预后相关的免疫球蛋白基因 免疫球蛋白相关基因(IGKC、IGHG1、IGHG4、IGLC2...
与未经治疗的患者相比,接受免疫治疗后,患者的Tregs细胞水平降低,CD8+T细胞和CD4辅助性T细胞水平升高,这些潜在肿瘤反应性T细胞的增多,表明HER2-negative TNBC患者接受免疫治疗后,T细胞的抗肿瘤能力增强,表现为接受免疫治疗后参与免疫应答的T细胞功能上调,TCR多样性更高。 值得注意的是,患者接受免疫治疗后,M1巨噬细胞的丰度...
采用EPclin界定为低风险的患者,远处复发风险仅为5.8%,RS低风险组,远处复发风险仅为10.1%。1/3的患者被划分到低风险组, EPclin低风险组,LN阴性的患者,10年的远处复发风险仅为0.5%,而RS低风险组为7%。 Dr Richard Buus谈到,本研究提示,EPclin相比RS评分可以更精准的界定低复发风险患者,这些患者可以规避化疗。此外,...
共识声明1.1:在临床实践中,2018年美国临床肿瘤学会和美国病理学会(ASCO/CAP)指南将HER2 IHC 0、1+、2+/ISH- 未扩增的肿瘤定义为“HER2阴性(HER2-negative)”。根据DESTINY-Breast04研究,“HER2低表达(HER2-low)”定义为HER2 IHC 1+...
[4]Palmieri, Carlo et al. “Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel ...
[4]Palmieri, Carlo et al. “Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel ...
[2]Zhang LH, Song GH, Shao B, et al. The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis[J]. Anticancer Drugs, 2022, 33(1):e635-e643. doi: 10.1097/CAD...
[7].Fujii T, Kogawa T, Dong W, Sahin AA, Moulder S, Litton JK, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol 2017;28:2420–8.* 本文由阿斯利康提供支持，仅供医疗专业人士参考 审批编号：CN-106964 有效期至：2023-12-6 *此...
1、GS4-10 Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. 2021 SABCS 2、Yi Z, Rong G, Guan Y, et al. Molecular landscape and efficacy of HER...
phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAI...